Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. News
  7. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica International : strengthens the management team

04/29/2021 | 05:08am EDT

Biovica, active in cancer diagnostics, today announced that the company has strengthened the management team with Helle Fisker as new commercial manager and Joakim Arwidson as new quality and regulatory manager.

Helle Fisker has more than 25 years of experience in commercializing both diagnostics and pharmaceuticals in oncology and other areas. In total, Helle has been involved in launching over 30 treatments and vaccines, and more than 350 medical products worldwide.

Joakim Arwidson has more than 25 years of experience in life science with experience in quality and regulatory affairs from development, production, market introduction and market follow-up in North America, Europe and Asia. Joakim has completed 14 successful 510(k) processes in oncology and theranostics (combining treatment and diagnosis of tumors).

“We are very pleased to strengthen our organization with Helle Fisker and Joakim Arwidson in this exciting phase for Biovica. Their vast experience will be a key part of succeeding with our upcoming launch and the realization of our vision, better outcome of treatment for cancer patients,” said Anders Rylander, CEO of Biovica.

Helle Fisker and Joakim Arwidson will be part of Biovica's management team.

© Modular Finance, source Nordic Press Releases

All news about BIOVICA INTERNATIONAL AB (PUBL)
09/15BIOVICA INTERNATIONAL : DiviTum«TKa results from SWOG study published in Clinica..
AQ
09/15Biovica Announces DiviTum«TKa results from SWOG study published in Clinical C..
CI
09/14BIOVICA INTERNATIONAL : Promising DiviTumTKa results from BioItaLEE study presen..
AQ
09/13BIOVICA INTERNATIONA : Biovica International
AQ
09/13BIOVICA INTERNATIONAL : provides update on FDA application process
AQ
09/13Biovica International AB Provides Update on FDA Application Process
CI
08/31BIOVICA INTERNATIONAL : Announcement from Biovica International's annual general..
AQ
08/31BIOVICA INTERNATIONAL : DiviTum«TKa approaching FDA approval
AQ
08/27BIOVICA INTERNATIONAL : CEO's presentation ahead of the 2021 Annual General Meet..
AQ
08/10BIOVICA INTERNATIONAL : strengthens management team
AQ
More news
Financials
Sales 2022 48,6 M 5,61 M 5,61 M
Net income 2022 -32,6 M -3,75 M -3,75 M
Net cash 2022 252 M 29,0 M 29,0 M
P/E ratio 2022 -52,5x
Yield 2022 -
Capitalization 1 506 M 173 M 174 M
EV / Sales 2022 25,8x
EV / Sales 2023 8,26x
Nbr of Employees 20
Free-Float 41,9%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 53,00 SEK
Average target price 103,00 SEK
Spread / Average Target 94,3%
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Lars Erik Holmqvist Chairman
Mattias Bergqvist Director-Clinical Development
Otti Bengtsson Gref Director-Research & Development
Sector and Competitors